BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 17173234)

  • 1. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
    Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO; Olatunji PO; Salami AK; Odeigah L; Iseniyi JO
    Niger J Clin Pract; 2008 Dec; 11(4):312-5. PubMed ID: 19320401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
    Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
    AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in weight and lean body mass during highly active antiretroviral therapy.
    Shikuma CM; Zackin R; Sattler F; Mildvan D; Nyangweso P; Alston B; Evans S; Mulligan K;
    Clin Infect Dis; 2004 Oct; 39(8):1223-30. PubMed ID: 15486848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
    Olawumi HO; Olatunji PO
    HIV Med; 2006 Sep; 7(6):351-5. PubMed ID: 16903978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
    AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
    Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
    Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on weight and height with the use of HAART in HIV-infected children.
    Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
    Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.